A small device implanted just beneath the skin, roughly the size of a large postage stamp and weighing about two grams, kept ...

The FDA has approved Awiqli, the first once‑weekly long‑acting basal insulin, for adults with type 2 diabetes, which offers ...

CNW/ -- (SSE: 603087) today announced that two pivotal phase 3 clinical trials, SUPER-1 and SUPER-2, evaluating ...

Some patients with type 2 diabetes will be able to switch from daily insulin injections to this first-of-its-kind once-weekly ...

For over a century, scientists have chased the dream of insulin pills, but the digestive system kept destroying the drug ...

“Insulin injections remain a daily burden for many patients,” said Shingo Ito, an associate professor at Kumamoto University ...

Most diabetes patients must carefully monitor their blood sugar levels and inject insulin multiple times per day, to help ...

(1,2) "Awiqli (R) is an important new option that meets a real need as the first FDA-approved, once-weekly basal insulin for adult patients with type 2 diabetes. It's helping to reframe what basal ...

A major challenge for people who have a form of diabetes is the need to regulate the glucose levels in their body. Normally this is where the body’s insulin-producing cells would respond to glucose ...

Researchers in Japan have reported a significant step in the long‑standing scientific effort to develop an insulin medication ...

The primary factor behind diabetes is that your body may not make enough insulin (type 1 diabetes) or it fails to respond to the insulin your pancreas releases, which is known as insulin resistance ...

“Insulin injections remain a daily burden for many patients,” said Associate Professor Shingo Ito. “Our peptide-based ...